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1  | INTRODUC TION
The COVID-19 pandemic has had a profound and direct impact 
on the health and lives of the global population and has placed a 
huge burden on healthcare systems (Mayor, 2020; CDC, 2020a,b; 
WHO,	2020a).	As	the	pandemic	spread,	many	countries	took	dras-
tic actions aiming to curtail the spread of the disease and to avoid 
overwhelming local, regional and national health care services. 
Much of routine health care diverted to COVID-19; non-COVID 
primary care and specialty care services were downscaled or com-
pletely halted. (Jones et al., 2020; The Lancet Oncology, 2020a; 
WHO, 2020a). Fear of contracting COVID-19 also led to patient 
reluctance towards attending in-person visits (CRUK, 2020; Jones 
et al., 2020). Consequently, timely cancer diagnosis may have been 
affected, with early reports suggesting that the decreased num-
ber of general practitioner (GP) consultations, combined with the 
minimalised capacity for non-COVID care, may have had a serious 
impact on the diagnostic pathway (CRUK, 2020; Richards et al., 
2020; Dinmohamed et al., 2020; EHRN, 2020; WHO, 2020a). For 
example,	 in	 the	Netherlands,	 the	 number	 of	 new	weekly	 diagno-
ses	of	 all	 cancers	 (except	 skin)	 dropped	 to	73%	of	normal	 and	 to	
39%	of	normal	for	skin	cancers	 (Dinmohamed	et	al.,	2020).	 In	the	
United	States,	a	data	set	that	included	2.7	million	patients	from	39	
health systems, showed that appointments for cervical, colon and 
breast	 cancer	 screening	 decreased	 by	 86%–95%	 in	 March	 2020	
(EHRN,	2020).	In	Australia,	despite	relatively	few	COVID-19	cases,	
anecdotal accounts suggest while overall GP consultations have 
not fallen dramatically, the switch to telemedicine has been asso-
ciated with reduced pathology and radiology requests, reduced re-
ferrals for suspected cancer, and early evidence of reduced cancer 
incidence (Cunningham, 2020). In countries with organised cancer 
screening programmes, services were suspended or reduced in ca-
pacity, and in some cases, staff and laboratory resources pivoted to 
support COVID-19 efforts (CRUK, 2020; Dinmohamed et al., 2020).
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Cancer is the leading cause of death in many countries and its 
prognosis and burden are highly dependent on disease stage at diag-
nosis	(De	Angelis	et	al.,	2014).	In	countries	with	a	gatekeeper	health-
care	system	around	86%	of	cancer	patients	are	diagnosed	after	initial	
symptomatic	presentation	 to	 the	GP	 (Hansen,	Vedsted,	Sokolowski,	
Søndergaard, & Olesen, 2011). Over the past decade, there have 
been concerted efforts to promote early presentation of patients to 
primary care and timely referral by GPs to specialty care, aiming to 
reduce diagnostic delays (Emery et al., 2014; Hamilton, Walter, Rubin, 
&	Neal,	2016;	Rubin	et	al.,	2015).	The	COVID-19	pandemic	likely	al-
ready has and will continue to have an effect on all intervals of the 
diagnostic pathway (Dobson, Russell, & Rubin, 2014; Weller et al., 
2012).	Specifically,	it	is	likely	to	impact	the	patient interval, as patients 
postpone presentation of symptoms; the primary care interval, as GP 
evaluations are delayed, unavailable or substandard by re-organisation 
and use of telemedicine, and the secondary care interval, as reallocation 
of specialised diagnostic and care capacity increases times to consul-
tation, testing and diagnosis (CRUK, 2020; Dobson et al., 2014; Jones, 
2020). Consequences for cancer-related burden and mortality seem 
inevitable	and	will	likely	be	long-lasting	(Richards	et	al.,	2020).
The COVID-19 pandemic is at different stages around the 
world. Regardless of the prevailing status, it is critical that the 
cancer diagnostic pathway is preserved. This means we must 
find mechanisms to prepare for the first wave's impact, adapt to 
its impact, and/or recover while preparing for the next. To this 
end, we need to support effective and well-balanced COVID-
19 measures that support the role of the GP as the protector of 
the healthcare system and as the provider of holistic care for the 
population. Finally, we need to learn from these experiences, as 
COVID-19 may become a continuous obstacle for organising safe 
and effective cancer diagnostic care.
As	 members	 of	 the	 Cancer	 and	 Primary	 Care	 Research	
International	Network	(Ca-PRI),	we	propose	the	following	essential	
components that should be part of an ongoing approach to itera-
tively and continuously find the optimal balance between minimising 
the negative impact of the COVID-19 pandemic while safeguarding 
timely cancer diagnosis. Figure 1.
1.1 | Assess and anticipate COVID-19 burden
Measures	taken	during	the	COVID-19	pandemic	require	real-time,	
accurate evidence regarding local and national COVID-19 disease 
burden.	 We	 propose	 that	 healthcare	 communities	 working	 with	
their local or national public health agencies regularly estimate, 
share and evaluate information regarding the status (both current 
and anticipated) of the COVID-19 disease burden in their respec-
tive populations. Collaboratively charting and preparing for the 
F I G U R E  1   Essential components of an iterative, continuous approach to find optimal balance between impact of COVID-19 pandemic 
while safeguarding timely cancer diagnosis
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anticipated	impact	enables	a	well-balanced	strategy	that	takes	into	
account the expected changes in the incidence and prevalence of 
mild, serious and complicated COVID-19 infections. The COVID-
19 burden should then be balanced with the diagnostic and clinical 
care capacity for cancer and other serious conditions. The World 
Health Organization (WHO) provides helpful tools to guide COVID-
19-related measures (WHO, 2020b, c).
1.2 | Enhance telemedicine in primary care, but 
with caution
Expanding telemedicine seems vital during the COVID-19 pandemic; 
however,	 it	 also	 has	 potential	 risks	 that	must	 be	 considered	 (Gray,	
Joseph, & Olayiwola, 2020). First, cancer diagnosis often requires 
a physical examination, hence telemedicine has clear limitations. 
Second,	there	are	known	issues	regarding	digital	inequality,	or	dispar-
ities in both the ability to access and to use telemedicine, within local, 
regional, national, and global populations (Gray et al., 2020; Helsper, in 
press; Nouri, Khoong, Lyles, & Karliner, 2020; Velasquez & Mehrotra, 
2020) and efforts to overcome these disparities are needed (Citizens 
online, 2020; Gray et al., 2020; Velasquez & Mehrotra, 2020). We 
recommend that access to primary care is optimised and expanded 
with the use of telemedicine, with attention for these potential nega-
tive consequences. We propose that practices not solely rely on 
telemedicine but also plan for in-person office or home visits. This 
may be done following a screening or triage telemedicine encounter, 
which assesses for COVID-19 symptoms and the need for and type 
of physical examination. COVID-19 evaluations should be diverted to 
other settings, thus allowing for reduced spread of disease, efficient 
use of primary care capacity as well as optimising the use of personal 
protective	materials	(e.g.	masks)	and	facilitating	in-person	consulta-
tions with individuals concerned about contacting COVID-19. The 
in-person or home visits should follow recommended measures to 
prevent contamination, such as minimal “touch points” with the office 
staff and clinicians (WHO, 2020d). It is also important to note that 
telemedicine does require preparation and training. Strategies for 
telemedicine have been described, including guides for its adoption 
in primary care (BJGP Life, 2020; Shaw et al., 2020). Further, techno-
logical as well as financial incentives and reimbursement may support 
increased use of telemedicine (Shachar, Engel, & Elwyn, 2020). With 
these considerations in mind, we believe that telemedicine can be 
used in ways that support cancer diagnosis.
1.3 | Optimise primary care and specialty 
care workflows
Healthcare settings should evaluate primary and specialty care ca-
pacity	and	explore	potential	 for	collaborative	workflows,	 including	
those that allow for timely evaluation of potential cancer symptoms. 
For example, within the primary care setting, GP practices may 
consider reorganising on a regional level, thereby expanding their 
operations	as	a	network	to	jointly	provide	care	for	their	patient	pop-
ulations (including COVID-19 and non-COVID-19). This could include 
dividing GP practices into those that do and do not see patients with 
suspected COVID-19, thus saving protective resources and enabling 
the continuation of “normal” (face-to-face) primary care practice. 
The	feasibility	of	such	re-organisation	 is	 likely	dependent	on	 local,	
regional or national policies, health insurance (for some countries), 
access to medical records, and geography, among others. In a shared 
effort between primary and secondary care, the efficient and flex-
ible use of diagnostic and referral capacity should be developed. 
This collaboration may include agreements on prioritisation and tri-
age of patients with and without COVID-19 as well as strategies to 
remove	barriers	for	diagnostic	workup	related	to	the	availability	of	
specialised cancer diagnostic equipment or personnel. For example, 
this could include facilitated access to personal contact between the 
GP and specialist in order to triage priority for individual patients, or 
direct primary care use of diagnostic equipment which would nor-
mally need referral to secondary care (additionally addressed below).
1.4 | Expand access to diagnostic services
We propose that access to specialty care diagnostic services is sys-
tematic	but	flexible.	A	tailored	diagnostic	pathway,	which	takes	into	
account the reduced availability of some investigations during the 
pandemic, should be guided by triage guidelines (adapted for use 
during the pandemic) for cancer symptoms in order to identify those 
who are at most urgent need of additional evaluation. For example, a 
breast lump, haemoptysis or rectal bleeding may warrant expeditious 
referrals to secondary care; whereas less specific symptoms such as 
fatigue or weight loss may warrant additional telemedicine consulta-
tion. Further, some diagnostic tests not typically used by GPs in some 
countries (e.g. faecal immunochemical test for colorectal cancer) may 
be expanded. The use of specialty care diagnostic services may also 
be broadened by joint consultations (with both primary care and pa-
tients) using telemedicine, or by promoting direct contact between 
GPs and secondary care physicians. Strengthening the GPs’ gate-
keeper	function	by	allowing	direct	access	to	diagnostic	facilities	that	
are currently only available to secondary care may also expedite diag-
nostic	workup	without	burdening	secondary	care	services.	Another	
consideration may be to set up temporary diagnostic sites, staffed by 
specialised teams, to prevent overcrowding of regular facilities and 
to reassure patients avoiding regular care for fear of infection. This 
approach	could	work	 if	 it	systematically	developed,	and	performed	
in a flexible manner, tailored for the urgency in each patient and with 
appropriate training. Handling patients who need investigation in this 
way	may	reduce	the	potential	backlog	and	further	delays	in	diagnosis.
1.5 | Identify and direct care to patients at risk
We	must	build	capacity	to	identify	patients	at	risk	of	suboptimal	or	
delayed	diagnostic	workup	for	cancer.	This	may	include	those	who	
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are	more	likely	to	“no	show”	or	postpone	GP	visits,	or	those	who	may	
have already been “lost” in the diagnostic pathway (Jefferson et al., 
2019; Sheridan et al., 2019). Patients with chronic diseases and older 
age	may	warrant	extra	attention,	as	they	are	at	higher	risk	of	cancer	
but paradoxically are also advised to practise social distancing and 
remain	at	home.	These	patients	at	risk	should	be	identified	in	each	
community and GP practice as these individuals may differ between 
practices, regions and/or countries. For example, patients who are 
more	 likely	 to	 “no	show”	or	postpone	GP	visits	may	 include	 those	
who are less willing or unable to access the GP through telemedicine, 
those without insurance (particularly in countries without universal 
health care), those in underserved communities, those with underly-
ing	psychiatric	 conditions	 (likely	 to	worsen	during	COVID-19),	 and	
those with cultural and/or language barriers (Jefferson et al., 2019; 
Sheridan et al., 2019). Those already lost in the diagnostic pathway 
may include patients who were scheduled for specialty care con-
sultation or testing but whose appointments were cancelled due 
to COVID-19, those who relayed concerning symptoms to primary 
care	during	the	pandemic	peak	and	were	not	referred	for	additional	
evaluation, and lastly those who may had symptoms but never re-
ported them. Identifying these patients requires a multifaceted ap-
proach, including reviewing appointment logs, primary care records 
(using both diagnostic coding and free text coding), and individual 
physician, practice or healthcare system panels. Direct outreach 
with	these	patients	at	 risk,	 in-person	or	on	a	 larger	scale,	advising	
regular	“check-ins”	using	telemedicine	will	be	critical.	Expansion	of	
home visits, using required precautions, may be needed.
1.6 | Activate patient outreach and education
To prevent persistent underutilisation of primary care services, 
there must be a concerted effort to educate patients about the 
need to report suspicious symptoms that may indicate cancer and 
address them with their primary care clinicians. Improving outreach 
and education involves collaboration with local and national cancer 
societies, charitable organisations, public health officials and the 
media. Public service advertisements may be shared on traditional 
media channels, public spaces, as well as social media. Educating 
patients also means educating families, promoting social awareness 
to	keep	an	eye	on	(symptoms	among)	loved	ones,	and	encouraging	
help-seeking	behaviours.	Campaigns	are	needed	to	encourage	indi-
viduals	to	seek	medical	attention	and	reassure	them	that	(even	if	the	
symptom has improved or disappeared), they can safely visit their 
GP (with recommended safeguards outlined by the WHO applied by 
patients (e.g. washing hands) and by practices (e.g. using protective 
materials)) (WHO, 2020d).
1.7 | Address psychosocial needs
Care during the COVID-19 pandemic requires focused atten-
tion on and proactive monitoring of psychological, financial and 
interpersonal issues (Dubey et al., 2020), especially since they are 
often pervasive among those with cancer. Patterns of COVID-19 in-
cidence	 and	mortality	have	 already	 shown	 stark	disparities	 across	
the	 globe	 (WHO,	 2020e),	 and	 the	 impact	 of	 COVID-19	will	 likely	
continue	 to	 be	 felt	most	 acutely	 and	 long-term	 among	 at	 risk	 pa-
tient populations. It is critical that GPs recognise that there will be 
delayed cancer diagnoses, and for some individuals this will result in 
diagnosis of late-stage disease, and possibly at a non-curative stage. 
Whether or not this late-stage diagnosis was directly attributable 
to COVID-19 for an individual patient may be difficult to determine, 
but this may agonise patients and their families. Patients may blame 
themselves for waiting to contact their GP or be angry at the per-
ceived “closing down” of routine health services, while at the same 
time	feeling	guilty	because	they	know	many	others	needed	priority	
care for COVID-19. Distress related to a perceived or bona fide de-
layed diagnosis, coupled with the social isolation and increased com-
munity stress due to COVID-19, may exacerbate the psychological 
burden among patients (Röhr et al., 2020). Integrating psychosocial 
screening in routine GP care will be critical in order to assess and ad-
dress these needs for months and years to come (Holland, Watson, 
& Dunn, 2011).
2  | CONCLUSION
COVID-19 has drastically affected health care around the world, and 
its effects on cancer diagnosis are undeniable. In attempts to recover 
and mitigate these effects, we recommend an approach to itera-
tively and continuously find the optimal balance between minimising 
the negative impact of the COVID-19 pandemic while safeguarding 
the diagnostic cancer pathway. This effort should be collaborative 
and include primary care, secondary care, patient organisations and 
policy	makers.	Changes	in	disease	burden	and	healthcare	system	ca-
pacity should be regularly measured and deliberated between the 
secondary and primary care community. Knowledge should continu-
ously be used to improve systematic, flexible and efficient triage of 
patients and iteratively improve the balance between referrals that 
are deemed urgent and delaying others that can be safely deferred. 
The use of telemedicine should be enhanced, but with careful con-
sideration	of	its	potential	risks.	Psychosocial	care	needs	and	patient	
education must remain at the forefront of the ongoing efforts.
The approach we have outlined is a starting point to guide ef-
forts to promote timely cancer diagnosis during COVID-19 and is 
not meant to be comprehensive in scope. We emphasise that in 
this crisis situation, situations change and evidence accumulates 
daily, so we will need to continuously examine, measure and refine 
our strategies. Our recommendations focus on cancer diagnosis, 
though	we	 acknowledge	 the	 effects	 of	 the	COVID-19	pandemic	
on other phases of the cancer care continuum (Chan et al., 2020; 
Gosain	 et	 al.,	 2020;	 Mehta	 &	 Smith,	 2020;	 Nekhlyudov	 et	 al.,	
2020; The Lancet Oncology, 2020b; WHO, 2020a) and that ongo-
ing management of chronic medical conditions among those with 
cancer	should	not	be	overlooked.	Further,	these	recommendations	
     |  5 of 6COMMENTARY
may be most applicable for high-income and middle-income coun-
tries and thus may be of less benefit for low-income countries 
without sufficient primary and specialty care and limited infra-
structure	including	electricity	and	internet	access.	As	we	already	
noted, relying on telemedicine in less resourced communities may 
worsen disparities.
In summary, COVID-19 has led to challenges for an efficient di-
agnostic pathway and in the provision of health care overall. It has 
further	 complicated	 the	promise	of	 early	 cancer	diagnosis.	As	 the	
pandemic continues to affect global societies, this is an opportunity 
to overcome the challenges by joining forces to carefully expedite 
the development and use of promising solutions, implement collab-
orative changes, continuously learn and adapt our interventions. For 
primary care, COVID-19 has offered an opportunity to find innova-
tive ways to restructure practices, adapt to telemedicine and dig-
ital	 triaging	systems,	and	to	 launch	collaborative	methods	to	work	
with specialty care, community groups and patient populations. 
Challenges will undoubtedly remain, but we need to begin the dia-
logue and use this newly acquired potential to balance the negative 
impact of the COVID-19 pandemic with safeguarding timely cancer 
diagnosis.
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